8-K - Acrivon Therapeutics, Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Acrivon Therapeutics held a KOL panel on February 27, 2026, at the ESGO Congress disclosing interim data from the ACR-368 Phase 2b registrational-intent trial (ACR-368-201/GOG3082) in endometrial cancer. Arm 1 (BM+ cohort, N=40) showed ORR of 39% (95% CI 24-56), DCR 80.6%, with favorable safety and high activity in serous subtype.

Key Takeaways

1KOL panel presented interim ACR-368 data from Arm 1 (BM+, N=40): ORR 39% (95% CI 24-56), DCR 80.6%, CBR 61.3%

2ORR 44% in BM+ patients with ≤2 prior lines (N=35); 52% in serous subtype with ≤2 prior lines (N=23)

3Favorable safety: Grades 3/4 TRAEs include anemia 27%, neutropenia 25%, thrombocytopenia 22%; no fatal TRAEs

4Arm 2 (BM-, N=48): ACR-368 + ULDG; Arm 3 serous all-comer (N=~90) enrolling with completion Q4 2026

5Patients: relapsed after platinum and anti-PD-(L)1; median 2 prior lines; 50% serous in Arm 1

6Study expanded to >20 EU sites; primary endpoint ORR by RECIST 1.1

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Secti

Regulation Fd

9.01

Financial Statements and Exhibits. Exhibit Number Description 99.1 KOL Panel Slides 104 Cover Page Interactive Data File (embedded within the Inline XBRL docume

Exhibits Only

Exhibits (2)

8-K

99.1

EX-99.1